Allergan just got exclusive access to a treatment that could revolutionize how we treat genetic diseases

0
8
Allergan just got exclusive access to a treatment that could revolutionize how we treat genetic diseases
Allergan CEO Brent Saunders

March 14 (Reuters) – Allergan said on Tuesday it would get exclusive access and the option to license up to five of Editas Medicine’s experimental gene-editing-based eye treatments under a research and development deal between the two companies.

The five eye programs include Editas’s lead drug, which is currently in pre-clinical development, to treat a rare, inherited eye disorder called Leber Congenital Amaurosis, the two companies said in a joint statement.

Editas’ gene-editing technology is called CRISPR and it is expected to revolutionize the treatment of genetic diseases. CRISPR works as a type of molecular scissors that can trim away unwanted pieces of genetic material, and replace them with new ones.

Read the original article onReuters. Copyright 2017. Follow Reuters on Twitter.

Previous Published: https://goo.gl/rqdDSG